Hyperprogression—Immunotherapy-Related Phenomenon vs Intrinsic Natural History of Cancer—In Reply
Author:
Affiliation:
1. Department of Cancer Medicine, Gustave Roussy, Villejuif, France
2. Deparment of Radiology, Gustave Roussy, Villejuif, France
3. Paris-Sud University, Orsay, France
Publisher
American Medical Association (AMA)
Subject
Oncology,Cancer Research
Link
http:///jamaoncology/article-pdf/5/5/744/17575105/jamaoncology_ferrara_2019_lr_190005.pdf
Reference6 articles.
1. Hyperprogressive disease in patients with advanced non-small cell lung cancer treated with PD-1/PD-L1 inhibitors or with single-agent chemotherapy.;Ferrara;JAMA Oncol,2018
2. Clinical benefit for patients with non-small cell lung cancer enrolled in phase I trials.;Levy;Onkologie,2013
3. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer.;Borghaei;N Engl J Med,2015
4. Durvalumab with or without tremelimumab vs platinum-based chemotherapy as first-line treatment for metastatic non-small cell lung cancer: MYSTIC.;Rizvi;Ann Oncol,2018
5. Fast progression in patients treated with a checkpoint inhibitor (cpi) vs chemotherapy in OAK, a phase III trial of atezolizumab (atezo) vs docetaxel (doc) in 2L+ NSCLC.;Gandara;Ann Oncol,2018
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Gut Microbiota and Breast Cancer: The Dual Role of Microbes;Cancers;2023-01-10
2. Impact of response patterns for patients with advanced acral melanoma treated with anti-programmed death-1 monotherapy;British Journal of Dermatology;2022-10-20
3. Fast progression in non–small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel;Journal for ImmunoTherapy of Cancer;2021-03
4. Comparison of Fast-Progression, Hyperprogressive Disease, and Early Deaths in Advanced Non–Small-Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or Chemotherapy;JCO Precision Oncology;2020-11
5. Hyperprogressive Disease upon Immune Checkpoint Blockade: Focus on Non–small Cell Lung Cancer;Current Oncology Reports;2020-04-16
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3